Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Opna Bio LLC
Pfizer
KitovPharma
University of Utah
Cedars-Sinai Medical Center
Mayo Clinic